LuciGefi 250mg (Gefitinib) is a prescription medication used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients with specific EGFR gene mutations. It is a tyrosine kinase inhibitor (TKI). By blocking the Epidermal Growth Factor Receptor (EGFR) protein, the medication inhibits the growth and division of cancer cells. It is targeted therapy for tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Lung Cancer
Order Now +8801575308158
LuciGefi 250mg (Gefitinib)
LuciGefi 250mg is a prescription medication containing the active ingredient Gefitinib, a targeted therapy used to treat advanced or metastatic non-small cell lung cancer (NSCLC). It works as a tyrosine kinase inhibitor (EGFR-TK) that blocks specific proteins, slowing or halting the division and spread of cancer cells.
Reviews
There are no reviews yet.